- Time:
Immune checkpoint inhibitors have significantly improved the survival of patients with various types of cancers, yet most advanced cancer patients will need additional treatment options. Intratumoral myeloid dendritic cells play a pivotal role in reinvigorating the cancer-immunity cycle and re-licensing antitumor cytotoxic T lymphocytes. In this exciting new webinar co-hosted by GEN and Clinical OMICs, we will explore the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials. Additionally, we will hear how on-treatment biopsies are analyzed for cellular changes with immunohistochemistry and multiplexed immunofluorescence, which could serve as a surrogate biomarker.
A live Q&A session followed the presentations, offering you a chance to pose questions to our expert panelists.
Dept of Medical Oncology
University Hospital Brussels
Senior Field Applications Scientist, Ultivue
Produced with support from:
